Sector News

U.S. approves GSK’s purchase of Novartis vaccine business: companies

November 27, 2014
Life sciences
(Reuters) – GlaxoSmithKline won U.S. antitrust approval to buy Novartis AG’s vaccine business, with the exception of influenza vaccines, the two companies said on Wednesday.
 
The deal is part of a three-way transaction unveiled in April, which includes Britain’s GSK buying the vaccines business of Novartis, the Swiss company purchasing GSK’s cancer drugs, and the two groups tying up in consumer healthcare.
 
The U.S. Federal Trade Commission had previously announced on Wednesday that it approved the consumer health care joint venture on the condition that Novartis sell its Habitrol nicotine patch.
 
Novartis and Glaxo, which has Nicoderm CQ, are two of only three companies that sell nicotine patches to U.S. retailers, the FTC said.
 
(Reporting by Diane Bartz; Editing by Diane Craft)

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”